CMS proposes Medicare cover new diagnostic test for cancer
The Centers for Medicare & Medicaid Services this week released for comment a proposal that Medicare cover diagnostic laboratory tests that use Next Generation Sequencing for patients with a breast or ovarian cancer that may be inherited. The test used must be approved by the Food and Drug Administration, ordered by a treating physician for a patient not previously tested using NGS, and performed in a laboratory certified under the Clinical Laboratory Improvement Amendments program, among other requirements. Under the proposal, Medicare administrative contractors also could decide to cover the tests for patients with other cancers that may be inherited.
Related News Articles
Headline
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase…
Headline
The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for…
Headline
The AHA Jan. 26 expressed support and provided its perspective on certain provisions within the Centers for Medicare & Medicaid Services’ proposed…
Headline
The AHA Jan. 20 made recommendations to Congress on modernizing the Medicare Access and CHIP Reauthorization Act. Among the proposals, the AHA recommended…
Headline
The comment period for the Centers for Medicare & Medicaid Services' proposed rule for policies governing the Medicare Advantage and Part D programs for…
Headline
The Medicare Payment Advisory Commission Jan. 15 voted to recommend that Congress update Medicare payment rates for hospital inpatient and outpatient services…